A Randomized Controlled trial of Subcutaneous Autologous Serum Therapy versus Subcutaneous Histoglobulin Injection in treatment of Idiopathic Chronic Urticaria.

Chronic Idiopathic Urticaria (CIU) is a challenging dermatological condition characterized by spontaneous recurrent wheals and pruritus lasting for six weeks or more significantly impacting patients quality of life.

While antihistamines remain the first-line treatment a considerable proportion of patients fail to achieve satisfactory symptom control necessitating alternative immunomodulatory therapies.

Subcutaneous administration offers distinct advantages including enhanced immune modulation  gradual desensitization and sustained therapeutic effects with fewer systemic side effects compared to other routes.

Despite the potential benefits of both therapies there is a lack of head-to-head comparative studies evaluating their efficacy safety and long-term benefits in CIU.

Given these gaps in existing research this study aims to comparatively assess the efficacy of subcutaneous Histoglobulin versus subcutaneous autologous serum therapy in patients with CIU, focusing on symptom relief recurrence rates safety profiles and overall patient outcomes.